MedTrace Logo

Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients

NCT02474316 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2015-12-03

No results posted yet for this study

Summary

This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA treatment, HBeAg positive CHB patients who achieved HBV DNA\<1000copies/ml but HBeAb negative, will be randomized (1:1) into 2 study arms as follows:

Arm A: Peginterferon alfa-2a 180μg /wk plus NA 1 piece qd for 48 weeks Arm B: Entecavir 0.5mg qd for 48 weeks

Conditions

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a 180ug/wk s.c for 48 weeks

DRUG

nucleos(t)ide analgoue

nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Qing Xie · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474316 on ClinicalTrials.gov